Skip to main content
All lobbying firms

BRIDGEBIO PHARMA, INC.

Registrant on federal lobbying filings · filed 2025 to 2026

$0 Income reported
1 Clients represented
7 Filings counted
0 Former members lobbying

Income is the fees this registrant reported being paid to lobby. It also reported $2,620,000 of in-house lobbying expenses, which is what a registrant files when it lobbies for itself. 1 filing on this record was restated by a later amendment and is left out of every total here. Everything on this page is grouped by the registrant's LDA id (401107898), not by name.

 Clients 1
 Lobbyists named 2
  • SCOTT HINKLE 1 filing · through 2026 Sr. Leg. Assistant and Counsel, Policy Dir. and Counsel, Leg. Dir. and Counsel, Deputy Chief of Staff (CoS)/Leg. Dir./Counsel, CoS and Counsel, DC CoS and Coun…
  • TRIPP ADAMS 1 filing · through 2026 Staff Assistant and Legislative Correspondent for Sen. Johnny Isakson; Legislative Correspondent for Sen. Kelly Loeffler; Health Research Assistant and Staff M…

A lobbyist who previously held a covered government position must disclose it. We flag the ones whose name resolves to a member of Congress and link the ones still in our roster. The revolving door collects them across every firm.

 Reported by year 2 years
  • 2026 $1,430,000 3 filings
  • 2025 $1,190,000 4 filings
 Issues lobbied 1

The count is how many filings named that issue area. A filing reports one lump figure covering every issue on it, so the money above cannot be split between them.

 Agencies and chambers lobbied 2
  • HOUSE OF REPRESENTATIVES 7
  • SENATE 7
 Recent filings 8 total
Q3 report
BRIDGEBIO PHARMA, INC.
3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $510,000 expenses · posted Oct 19, 2026
View → Q2 report
BRIDGEBIO PHARMA, INC.
2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $500,000 expenses · posted Jul 20, 2026
View → Q4 amendment
BRIDGEBIO PHARMA, INC.
4th Quarter 2025 (Oct 1 - Dec 31) · House · Senate · $280,000 expenses · posted Jul 17, 2026
View → Q1 report
BRIDGEBIO PHARMA, INC.
1st Quarter 2026 (Jan 1 - Mar 31) · House · Senate · $420,000 expenses · posted Apr 20, 2026
View → Q4 report
BRIDGEBIO PHARMA, INC. Amended
4th Quarter 2025 (Oct 1 - Dec 31) · House · Senate · $270,000 expenses · posted Jan 20, 2026
View → Q3 report
BRIDGEBIO PHARMA, INC.
3rd Quarter 2025 (July 1 - Sep 30) · House · Senate · $270,000 expenses · posted Oct 20, 2025
View → Q2 report
BRIDGEBIO PHARMA, INC.
2nd Quarter 2025 (Apr 1 - June 30) · House · Senate · $320,000 expenses · posted Jul 17, 2025
View → Q1 report
BRIDGEBIO PHARMA, INC.
1st Quarter 2025 (Jan 1 - Mar 31) · House · Senate · $320,000 expenses · posted Apr 18, 2025
View →

Keep going

Filings through , the newest posted date on this record. Source: federal Lobbying Disclosure Act filings, synced daily. Money is self-reported by the filer and often rounded. Lobbying is legal, disclosed activity.

Report a problem